FAST STATS A 5-minute Review for the Evidence-Based Practitioner.

Slides:



Advertisements
Similar presentations
Mark Pletcher 6/10/2011 Quantifying Treatment Effects.
Advertisements

Meeting need and improving coverage workshop. Meeting need: calculating and improving coverage.
Reporting drugs and treatments Thomas Abraham JMSC 6090.
Comparing Two Proportions (p1 vs. p2)
Evidence-Based Medicine Critical Appraisal of Therapy Department of Medicine - Residency Training Program Tuesdays, 9:30 a.m. - 12:00 p.m., UW Health Sciences.
Reporting drugs and treatments Thomas Abraham. What we will learn today The difference between absolute and relative risk reduction A basic way to interpret.
 Try to determine causes and risk factors for disease by drawing connections between behaviors or exposures and diseases through observation alone.
Step 3: Critically Appraising the Evidence: Statistics for Harm and Etiology.
Extension Article by Dr Tim Kenny
Critical Appraisal of an Article on Therapy. Why critical appraisal? Why therapy?
Advances in Lung Transplantation: A Patient Guide David J. Lederer, M.D., M.S. Assistant Professor of Medicine New York Presbyterian Lung Transplant Program.
Measures of Disease Association Measuring occurrence of new outcome events can be an aim by itself, but usually we want to look at the relationship between.
ABCWINRisk and Statistics1 Risk and Statistics Risk Assessment in Clinical Decision Making Ulrich Mansmann Medical Statistics Branch University of Heidelberg.
Mathew J. Reeves BVSc, PhD Associate Professor, Epidemiology
Statistics for Health Care
TREATMENT 1 Evaluation of interventions How best assess treatments /other interventions? RCT (randomised controlled trial)
Statistical Thinking Experiments in the Real World
BS Evidence Based Medicine And Atrial Fibrillation.
Critical Appraisal of an Article on Therapy (2). Formulate Clinical Question Patient/ population Intervention Comparison Outcome (s) Women with IBS Alosetron.
Understanding study designs through examples Manish Chaudhary MPH (BPKIHS)
1 The Chemoprevention of Sporadic Colorectal Cancer Issues Surrounding a Benefit/Risk Analysis in Clinical Trials Mark Avigan MD CM Medical Officer Division.
The Bahrain Branch of the UK Cochrane Centre In Collaboration with Reyada Training & Management Consultancy, Dubai-UAE Cochrane Collaboration and Systematic.
Absolute, Relative and Attributable Risks. Outcomes or differences that we are interested in:  Differences in means or proportions  Odds ratio (OR)
 Mean: true average  Median: middle number once ranked  Mode: most repetitive  Range : difference between largest and smallest.
Copyright © 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 14 Screening and Prevention of Illnesses and Injuries: Research Methods.
Testing People Scientifically.  Clinical trials are research studies in which people help doctors and researchers find ways to improve health care. Each.
About OMICS Group OMICS Group International is an amalgamation of Open Access publications and worldwide international science conferences and events.
Statistics for nMRCGP Jo Kirkcaldy. Curriculum Condensed Knowledge Incidence and prevalence Specificity and sensitivity Positive and negative predictive.
Evidence Based Practice in Psychology – Lecture 3 May 31, 2007.
How to Analyze Therapy in the Medical Literature (part 2)
CAT 3 Harm, Causation Maribeth Chitkara, MD Rachel Boykan, MD.
Understanding real research 4. Randomised controlled trials.
Measures of Association Professor Mobeen Iqbal Shifa College of Medicine.
EBCP. Random vs Systemic error Random error: errors in measurement that lead to measured values being inconsistent when repeated measures are taken. Ie:
Evaluating Information and Presenting Risk Today’s Class Fact Sheet Assignment Review Evaluating Information Presenting Risk In-class Activity This week’s.
Statistics for clinicians Biostatistics course by Kevin E. Kip, Ph.D., FAHA Professor and Executive Director, Research Center University of South Florida,
November 5, 2014 Matthew Tuck, MD Hospitalist, Veterans Affairs Medical Center Assistant Professor of Medicine, George Washington University.
RATES AND RISK Daniel E. Ford, MD, MPH Johns Hopkins School of Medicine Introduction to Clinical Research July 12, 2010.
Which Treatment ? For a patient, 64-year-old male For a patient, 64-year-old male No HT, DM, Heart failure, LV dysfunction No HT, DM, Heart failure, LV.
Literature Appraisal Effectiveness of Therapy. Measures of treatment effect Statistical significance Odds ratio Relative risk Absolute risk reduction.
Measuring associations between exposures and outcomes
$100 $200 $400 $500 $300 $100 $200 $400 $500 $300 $100 $200 $400 $500 $300 $100 $200 $400 $500 $300 $100 $200 $400 $500 $300 Terms Clinical Trial Facts.
Risks & Odds Professor Kate O’Donnell. When talking about the chance of something happening, e.g. death, hip fracture, we can talk about: risk and relative.
Compliance Original Study Design Randomised Surgical care Medical care.
BIOSTATISTICS Lecture 2. The role of Biostatisticians Biostatisticians play essential roles in designing studies, analyzing data and creating methods.
Vanderbilt Sports Medicine Evidence-Base Medicine How to Practice and Teach EBM Chapter 5 : Therapy.
What about VIOXX?. Adenomatous Polyp Prevention on Vioxx (APPROVe) Vioxx (rofecoxib) versus Placebo Basic Clinical Trial Objective: Assess whether Vioxx.
From EBM to SDM: Michel Labrecque MD PhD Michel Cauchon MD Department of Family and Emergency Medicine Université Laval Teaching how to apply evidence.
Biostatistics Board Review Parul Chaudhri, DO Family Medicine Faculty Development Fellow, UPMC St Margaret March 5, 2016.
Risk Different ways of assessing it. Objectives Be able to define and calculate: Absolute risk (reduction) Relative risk (reduction) Number needed to.
What are the Chances Dr? Nick Pendleton. Can I have a Prostate Check? ?
2 3 انواع مطالعات توصيفي (Descriptive) تحليلي (Analytic) مداخله اي (Interventional) مشاهده اي ( Observational ) كارآزمايي باليني كارآزمايي اجتماعي كارآزمايي.
Number Needed to Treat Alex Djuricich, MD Indiana University School of Medicine Department of Medicine Ambulatory Rotation
HelpDesk Answers Synthesizing the Evidence
Patient Focused Drug Development An FDA Perspective
CRITICAL NUMBERS LIVING WITH RISK
Martha Carvour, MD, PhD March 2, 2017
From: Treatment of Blood Cholesterol to Reduce Risk for Atherosclerotic Cardiovascular DiseaseGrand Rounds Discussion From the Beth Israel Deaconess Medical.
NAPLEX preparation: Biostatistics
Dabigatran vs Warfarin in Patients with Atrial Fibrillation – Results
remember to round it to whole numbers
1 Information Mastery Skills Calculating RR, RRR, ARR and NNTs A. Bornstein, MD, FACC Assistant Professor of Medicine Weil Cornell Medical College New.
Interpreting Basic Statistics
ASPIRE CLASS 6: Interpreting Results and Writing an Abstract
Evidence Based Practice
The Research Question Background: Question:
EBM – therapy Dr. Tina Dewi J , dr., SpOG
Non-communicable disease, health, disease
Basic statistics.
Medical Statistics Exam Technique and Coaching, Part 2 Richard Kay Statistical Consultant RK Statistics Ltd 22/09/2019.
Presentation transcript:

FAST STATS A 5-minute Review for the Evidence-Based Practitioner

When evaluating medical literature, there are two important concepts absolute risk vs. relative risk number needed to treat

Relative Risk (RR) compares the probability of an event occurring in the exposed group vs. the non-exposed group. Absolute Risk & Relative Risk Absolute Risk (AR) describes the incidence of a condition in a population.

Example: Drug A prevents heart attacks (MIs) but also increases the risk of lung cancer. A placebo-controlled trial in 200 people (100 in each arm) found that there were three heart attacks in the treated group and six heart attacks in the placebo group. There were three cases of lung cancer in the treated group, and one in the placebo group. Drug APlacebo MIs 36 Lung Ca 31 Absolute Risk & Relative Risk

We might say that Drug A reduces heart attack risk by 50% or cuts heart attack rate in half. We could also say that the heart attack risk is reduced by 3%.

Drug APlacebo MIs 36 Lung Ca 31 Absolute Risk & Relative Risk We could also say that lung cancer risk increases by 2%. We could say that the lung cancer risk increases by 200%.

Absolute risk makes risks or benefits look smaller. Relative risk makes risks or benefits look bigger. Absolute Risk & Relative Risk

To be fair, both harms and benefits should be presented in absolute terms or relative terms. Absolute Risk & Relative Risk

Number Needed to Treat (NNT) is an important means of evaluating data. NNT is calculated by taking the reciprocal of the absolute difference between experimental groups. Another way is by dividing 100 by absolute risk. Number Needed to Treat

3% of the treatment group and 6% of the control group had heart attacks. The absolute difference is 3% because 6%-3%= 3% = 0.03 That means that 33 people must be treated with this drug to prevent one heart attack. -OR- Number Needed to Treat

Number Needed to Harm (NNH) is also calculated by taking the reciprocal of the absolute difference between experimental groups. Another way is by dividing 100 by absolute risk. Number Needed to Harm

3% of the treatment group developed lung cancer, compared to 1% of the placebo group. The absolute difference is 2% or So the NNH is 50, meaning that we would expect one additional case of lung cancer for every 50 people treated with Drug A. -OR- Number Needed to Harm

Drug APlacebo MIs 36 Lung Ca 31 One out of every 33 people treated with Drug A will be spared a heart attack; however, one out of every 50 people will develop lung cancer caused by Drug A. NNT vs. NNH

Now you understand the difference between absolute and relative risk, and you can calculate NNT and NNH. This information will help you make evidence-based decisions for your practice. Congratulations!

PharmedOut is a Georgetown University Medical Center project that advances evidence-based prescribing, and educates healthcare professionals about pharmaceutical marketing practices. Learn more about us at Cover art by Andrea Sikora, inspired by Wojtek Kozak Presentation layout by Andrea Sikora and Grace Doan Nov 2011 version 2.4